Cor Vasa 2008, 50(9):332-337 | DOI: 10.33678/cor.2008.117

Anthracycline-induced cardiomyopathy; an overview of the issue with special emphasis on cardioprotection

Luboš Kraus1,*, Pavel Lovas2, Darina Krausová1
1 Interní oddělení, Nemocnice s poliklinikou Nový Jičín
2 Radioterapie a. s., Nový Jičín, Česká republika

Anthracyclines belong to the most active cytotoxic agents for the treatment of a wide variety of solid tumors and hematological malignancies. An undesirable effect associated with chronic administration of anthracyclines is the induction of cardiomyopathy leading to congestive heart failure, usually refractory to common treatments. The issue of anthracycline--induced cardiotoxicity has not been solved to date and current efforts are focused on prevention and new therapeutic strategies. The aim of this overview is to discuss the issue of anthracycline-induced cardiotoxicity in terms of its pathophysiology, risk factors, diagnosis, and current options of cardioprotection in preventing anthracycline-induced cardio-myopathy.

Keywords: Anthracyclines; Cardiotoxicity; Cardiomyopathy; Cardioprotection

Published: September 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kraus L, Lovas P, Krausová D. Anthracycline-induced cardiomyopathy; an overview of the issue with special emphasis on cardioprotection. Cor Vasa. 2008;50(9):332-337. doi: 10.33678/cor.2008.117.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neilan TG, Blake SL, Ichinose F, et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007;116:506-14. Go to original source... Go to PubMed...
    2. Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005;112:3754-62. Go to original source... Go to PubMed...
    3. Valencia V, Martineza JG, Sogorba F, et al. Late anthracyclines cardiotoxicity associated with infection by Mycoplasma pneumoniae. A case report. International J Cardiol 2005;99;351-3. Go to original source... Go to PubMed...
    4. Granger CB. Prediction and prevention of chemotherapy-induced cardiomyopathy. Can it be done? Circulation 2006;114;2432-3. Go to original source... Go to PubMed...
    5. Bryant J, Picot J, Levitt G, et al. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Health Technol Assess 2007;11:26-7. Go to original source... Go to PubMed...
    6. Cardinale D, Kolombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006;114;2474-81. Go to original source... Go to PubMed...
    7. Germanakisa I, Kalmantib M, Parthenakis F. Correlation of plasma N-terminal pro-brain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Intern J Cardiol 2006;108:212-5. Go to original source... Go to PubMed...
    8. Neilan TG, Jassal DS, Perez-Sanz (tm), et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J 2006;27:1868-75. Go to original source... Go to PubMed...
    9. A Scientific statement from AHS, ACA, and ESC… The role of endomyocardial biopsy in the management of cardiovascular disease. Eur Heart J 2007;28:3076-93.
    10. Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of Adriamycin carditoxicity. Cancor 1973; 32:302-14. Go to original source... Go to PubMed...
    11. Escherich G, Gőbel U, Jorch N, et al. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klin Pediatr 2007; 219:134-8. Go to original source... Go to PubMed...
    12. Bryant J, Picot J, Barter L, et al. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancor 2007;96:226-30. Go to original source... Go to PubMed...
    13. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Sem Oncol 1992;19:670-86.
    14. Sessa C, Valota O, Geroni C. Ongoing phase I and II studies of novel anthracyclines. Cardiovasc Toxicko 2007;7:75-9. Go to original source... Go to PubMed...
    15. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancor. Ann Oncol 2007;18:70-3. Go to original source... Go to PubMed...
    16. Schlumberger M, Brugieres L, Gicquel C, et al. 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortikal carcinoma. Cancor 1991;67:2997-3000. Go to original source... Go to PubMed...
    17. Price FV, Chambers SK, Carcangiu ML, et al. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of sterine papillary serous carcinoma. Gynecol Oncol 1993;51:383-9. Go to original source... Go to PubMed...
    18. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline Chemotherapy. Drugs 2005;65:1005-24. Go to original source... Go to PubMed...
    19. Conklin KA. Coenzyme Q10 for Prevention of Anthracycline-Induced Cardiotoxicity. Integr Cancer Ther 2005; 4:110-30. Go to original source... Go to PubMed...
    20. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006;48:2258-62. Go to original source... Go to PubMed...
    21. Oliveira PJ, Rolo AP, Sardao VA, et al. Advantages in the use of carvedilol versus propranolol for the protection of cardiac mitochondrial function. Rev Port Cardiol 2004;23:1291-8. Go to PubMed...
    22. Flesch M, Maack C, Cremers B, et al. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999;100:346-53. Go to original source... Go to PubMed...
    23. Spallarossa P, Garibaldi S, Altieri P, et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 2004;37:837-46. Go to original source... Go to PubMed...
    24. Bien S, Riad A, Ritter ChA, et al. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res 2007;67:10428-35. Go to original source... Go to PubMed...
    25. Dowd NP, Scully M, Anderley SR, et al. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Incest 2001;108:585-90. Go to original source... Go to PubMed...
    26. Neilan TG, Jassal DS, Scully MF, et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumor suppression. Eur Heart J 2006;27:1251-6. Go to original source... Go to PubMed...
    27. Guido ABC, Haenen RM, Bruynzeel Anna ME, et al. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials. Cardiovasc Toxicol 2007;7:154-9. Go to original source... Go to PubMed...
    28. Ling L, Qiangrong P, Weidong H, et al. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clinical Cancer Research 2007;13:6753-60. Go to original source... Go to PubMed...
    29. Mukhopadhyay P, Ba'tkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol 2007;50:528-36. Go to original source... Go to PubMed...
    30. Wu S, Ko YS, Teng MS, et al. Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies. J Mol Cell Cardiol 2002;34:1595-607. Go to original source... Go to PubMed...
    31. Hamed S, Barshack I, Luboshits G, et al. Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 2006;27:1876-83. Go to original source... Go to PubMed...
    32. Fukazawa R, Miller TA, Kuramochi Y, et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol 2003;35:1473-9. Go to original source... Go to PubMed...
    33. Elbl L, Hrstková H, Chaloupka V, a spol. Poškození srdce protinádorovou léčbou. 1. vydání. Praha: Grada Publishing, 2002.
    34. Horan PG, McMullin MF, McKeown PP. Anthracycline cardiotoxicity. Eur Heart J 2006;27:1137-8. Go to original source... Go to PubMed...
    35. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5. Go to original source... Go to PubMed...
    36. Rosenthal DS, Braunwald E. Cardiac effects of radiation therapy and chemotherapy. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders Co, 2001:1746-51.
    37. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Safety 2000;22:263-302. Go to original source...
    38. Feenstra J, Grobbee DE, Remme WJ. Drug-induced heart failure. J Am Coll Cardiol 1999;33:1152-62. Go to original source... Go to PubMed...
    39. Edward TH, Yeh MD, Ann T, et al. Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. Circulation 2004;109;3122-31. Go to original source... Go to PubMed...
    40. Delgado RM, Nawar MA, Zewail AM, et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in murine model of doxorubicine-induced heart failure. Circulation 2004;109: 1428-33. Go to original source... Go to PubMed...
    41. Barry E, Alvarez JA, Scully RE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert opinion on Pharmacotherapy 2007; 8:1039-58. Go to original source... Go to PubMed...
    42. Chen B, Peng X, Pentassuglia L, et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007;7:114-21. Go to original source... Go to PubMed...
    43. Cortés-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 2007;7:56-60. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes